+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

  • PDF Icon

    Report

  • 265 Pages
  • November 2020
  • Region: Global
  • GlobalData
  • ID: 5205443
Summary

The publisher's Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Colorectal Cancer Diagnostic Tests are used for detection of CRC based on the detection and measurement of cancer-specific biomarker/antibody/antigen present in patient’s sample.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Colorectal Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Colorectal Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Colorectal Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Colorectal Cancer Overview
3 Products under Development
3.1 Colorectal Cancer - Pipeline Products by Stage of Development
3.2 Colorectal Cancer - Pipeline Products by Territory
3.3 Colorectal Cancer - Pipeline Products by Regulatory Path
3.4 Colorectal Cancer - Pipeline Products by Estimated Approval Date
3.5 Colorectal Cancer - Ongoing Clinical Trials
4 Colorectal Cancer - Pipeline Products under Development by Companies
4.1 Colorectal Cancer Companies - Pipeline Products by Stage of Development
4.2 Colorectal Cancer - Pipeline Products by Stage of Development
5 Colorectal Cancer Companies and Product Overview
6 Colorectal Cancer- Recent Developments 1887 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer
List of Tables
Table 1: Colorectal Cancer - Pipeline Products by Stage of Development
Table 2: Colorectal Cancer - Pipeline Products by Territory
Table 3: Colorectal Cancer - Pipeline Products by Regulatory Path
Table 4: Colorectal Cancer - Pipeline Products by Estimated Approval Date
Table 5: Colorectal Cancer - Ongoing Clinical Trials
Table 6: Colorectal Cancer Companies - Pipeline Products by Stage of Development
Table 7: Colorectal Cancer - Pipeline Products by Stage of Development
Table 8: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Diagnostic Assay - Colorectal Cancer - Product Status
Table 10: Diagnostic Assay - Colorectal Cancer - Product Description
Table 11: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 12: DNA Damage Response Deficiency Assay - Colorectal Cancer - Product Status
Table 13: DNA Damage Response Deficiency Assay - Colorectal Cancer - Product Description
Table 14: Ambergen Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Veracode - Colorectal Cancer - Product Status
Table 16: Veracode - Colorectal Cancer - Product Description
Table 17: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Cchek - Colon Cancer Confirmatory Test - Product Status
Table 19: Cchek - Colon Cancer Confirmatory Test - Product Description
Table 20: Cchek - Colon Cancer Recurrence Test - Product Status
Table 21: Cchek - Colon Cancer Recurrence Test - Product Description
Table 22: Cchek - Colon Cancer Screening Test - Product Status
Table 23: Cchek - Colon Cancer Screening Test - Product Description
Table 24: Cchek - Colon Cancer Treatment Monitoring Test - Product Status
Table 25: Cchek - Colon Cancer Treatment Monitoring Test - Product Description
Table 26: Anixa Diagnostics Corporation - Ongoing Clinical Trials Overview
Table 27: Cchek - Colon Cancer Screening Test - The Coupling of MDSCs with a Computational Analytic Method to Detect Solid Tumors
Table 28: Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 29: SimpliPro Colon-A - Product Status
Table 30: SimpliPro Colon-A - Product Description
Table 31: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Biomarker Test - Colorectal Cancer - Product Status
Table 33: Biomarker Test - Colorectal Cancer - Product Description
Table 34: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Finger Stick Test - Colon Cancer - Product Status
Table 36: Finger Stick Test - Colon Cancer - Product Description
Table 37: ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview
Table 38: ArtemixRx Prognostic Test - Colon Cancer - Product Status
Table 39: ArtemixRx Prognostic Test - Colon Cancer - Product Description
Table 40: Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 41: TheraLink Assay - Colorectal Cancer - Product Status
Table 42: TheraLink Assay - Colorectal Cancer - Product Description
Table 43: Bio Mark Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Diagnostic Test - Colorectal Adenoma - Product Status
List of Figures
Figure 1: Colorectal Cancer - Pipeline Products by Stage of Development
Figure 2: Colorectal Cancer - Pipeline Products by Territory
Figure 3: Colorectal Cancer - Pipeline Products by Regulatory Path
Figure 4: Colorectal Cancer - Pipeline Products by Estimated Approval Date

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abcodia Ltd
  • Almac Diagnostic Services Ltd
  • Ambergen Inc
  • Anixa Diagnostics Corporation
  • Applied Proteomics Inc
  • Arizona State University
  • Arrayit Corporation
  • ArtemixRx
  • Avant Diagnostics Inc
  • Bio Mark Ltd
  • Biocartis Group NV
  • Biodesix Inc
  • BioMarCare Technologies Ltd
  • BioMark Diagnostics Inc
  • BioMarker Strategies LLC
  • Biomoda Inc
  • Bioprognos SL
  • BioSystems International
  • Biotron Ltd
  • Calviri Inc
  • Castle Biosciences Inc
  • Catholic University of Leuven
  • Celcuity Inc
  • CellMax Life Inc
  • Cellmid Ltd
  • Ceres Nanosciences Inc
  • Cernostics Inc
  • ChemImage Corp
  • China Sky One Medical Inc
  • Columbia University
  • CS-Keys, Inc. (Inactive)
  • Di.V.A.L Toscana srl
  • DiagnoCure Inc. (Inactive)
  • Diazyme Laboratories Inc
  • DNAlytics SA
  • Duke University
  • EDP Biotech Corporation
  • EntreChem SL
  • Epigenomics AG
  • Eurobio Scientific SA
  • Eventus Diagnostics Inc (Inactive)
  • Exact Sciences Corp
  • Exiqon AS
  • Exosomics Siena SpA
  • Fina Biotech SL
  • Fox Chase Cancer Center
  • GenExosome Technologies Inc
  • GenomicTree Co Ltd
  • German Cancer Research Center
  • Ghent University
  • GlycoZym USA Inc
  • Health Discovery Corp
  • Hitachi Chemical Diagnostics Inc
  • Human Metabolome Technologies Inc
  • Ikonisys Inc
  • Institute of Molecular and Translational Medicine
  • InterGenetics Inc
  • Johns Hopkins University
  • King Abdullah University of Science and Technology
  • Kyo Diagnostics KK
  • Lab21 Ltd
  • Laboratorios Alpha San Ignacio Pharma S.L.
  • Leitat Technological Center
  • MabCure Inc
  • Master Diagnostica Sociedad Limitada
  • Matrix-Bio Inc
  • Max Delbruck Center for Molecular Medicine
  • Mayo Clinic
  • MDNA Life Sciences Inc
  • MDxHealth SA
  • Merrimack Pharmaceuticals Inc
  • Metabolon Inc
  • MetaStat Inc
  • Milagen Inc
  • Myriad Genetics Inc
  • Nanocytomics LLC
  • Norda ASA
  • Novel Bio-spectrum Technologies Inc (Inactive)
  • Nuclea Biotechnologies Inc. (Inactive)
  • Oncimmune (USA) LLC
  • OncoCyte Corp
  • Onconome, Inc. (Inactive)
  • Origin Sciences Ltd
  • Orion Genomics LLC
  • OTraces Inc
  • Oxford Cancer Biomarkers Ltd
  • Oxford Gene Technology Ltd
  • PleX Diagnostics Inc (Inactive)
  • Precision Biologics Inc
  • Prediction Sciences LLC (Inactive)
  • PreMD Inc (Inactive)
  • Prescient Medicine LLC
  • Protagen AG
  • Protein Alternatives SL
  • Qiagen NV
  • Quest Diagnostics Inc
  • Rabin Medical Center
  • Rhythm Biosciences Ltd
  • RISE Life Science Corp
  • Rosetta Genomics Ltd
  • Sanguine Diagnostics and Therapeutics Inc
  • Scienion AG
  • Seegene Inc
  • Shuwen Biotech Co Ltd
  • Sysmex Corp
  • Tel Aviv University
  • The Walter and Eliza Hall Institute of Medical Research
  • TheraDiag SA
  • Treos Bio Inc
  • Trinity College Dublin
  • Universal Diagnostics SL
  • University of Illinois at Chicago
  • University of Lyon
  • University of Michigan
  • University of Notre Dame
  • University of Texas MD Anderson Cancer Center
  • University of Turku
  • University of Washington
  • University of Wisconsin Madison
  • University of Zurich
  • US Biomarkers Inc
  • vall d hebron institut de Recerca
  • Vanderbilt University
  • Vastcon Inc
  • Viomics Inc.
  • VolitionRX Ltd
  • XEPTAGEN SpA